48. The compound of Claim 1, wherein the compound is



, or a pharmaceutically acceptable salt thereof.

49. The compound of Claim 1, wherein the compound is



, or a pharmaceutically acceptable salt thereof.

50. The compound of Claim 1, wherein the compound is



, or a pharmaceutically acceptable salt thereof.

51. A pharmaceutical composition comprising an effective amount of a compound of any one of Claims 1-50, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient or combination thereof.

52. Use of a compound of any one of Claims 1-50, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 51 for preparing a medicament for ameliorating or treating a HCV infection.

53. Use of a compound of any one of Claims 1-50, or a pharmaceutically acceptable salt thereof, for preparing a medicament for inhibiting NS5B polymerase activity of a hepatitis C virus.

54. Use of a compound of any one of Claims 1-50, or a pharmaceutically acceptable salt thereof, for preparing a medicament for inhibiting replication of a hepatitis C virus.

55. Use of a compound of any one of Claims 1-50, or a pharmaceutically acceptable salt thereof, for preparing a medicament for contacting a cell infected with a hepatitis C virus, thereby ameliorating or treating the HCV infection.

56. Use of a compound of any one of Claims 1-50 in the preparation of a medicament for ameliorating or treating a HCV infection, wherein the medicament is manufactured for use in combination with one or more agents selected from the group consisting of an interferon, ribavirin, a HCV protease inhibitor, a HCV polymerase inhibitor, a NS5A inhibitor, an antiviral compound, a compound of Formula (AA), a compound of Formula (BB) and a compound of Formula (CC), or a pharmaceutically acceptable salt of any of the aforementioned compounds.

57. Use of a compound of any one of Claims 1-50 in the preparation of a medicament for contacting a cell infected with a hepatitis C virus, wherein the medicament is manufactured for use in combination with one or more agents selected from the group consisting of an interferon, ribavirin, a HCV protease inhibitor, a HCV polymerase inhibitor, a NS5A inhibitor, an antiviral compound, a compound of Formula (AA) , a compound of Formula (BB) and a compound of Formula (CC), or a pharmaceutically acceptable salt of any of the aforementioned compounds.

58. The use of any one of Claims 56-57, wherein the one or more agents are selected from the group consisting of Compounds 1001-1016, 2001-2012, 3001-3014, 4001-4012, 5001-5012, 6001-6078, 7000-7027 and 8000-8016, or a pharmaceutically acceptable salt of any of the aforementioned compounds.

48. The compound of Claim 1, wherein the compound is



, or a pharmaceutically acceptable salt thereof.

49. The compound of Claim 1, wherein the compound is



, or a pharmaceutically acceptable salt thereof.

50. The compound of Claim 1, wherein the compound is



, or a pharmaceutically acceptable salt thereof.

51. A pharmaceutical composition comprising an effective amount of a compound of any one of Claims 1-50, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient or combination thereof.

52. Use of a compound of any one of Claims 1-50, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 51 for preparing a medicament for ameliorating or treating a HCV infection.

53. Use of a compound of any one of Claims 1-50, or a pharmaceutically acceptable salt thereof, for preparing a medicament for inhibiting NS5B polymerase activity of a hepatitis C virus.

54. Use of a compound of any one of Claims 1-50, or a pharmaceutically acceptable salt thereof, for preparing a medicament for inhibiting replication of a hepatitis C virus.

55. Use of a compound of any one of Claims 1-50, or a pharmaceutically acceptable salt thereof, for preparing a medicament for contacting a cell infected with a hepatitis C virus, thereby ameliorating or treating the HCV infection.

56. Use of a compound of any one of Claims 1-50 in the preparation of a medicament for ameliorating or treating a HCV infection, wherein the medicament is manufactured for use in combination with one or more agents, or pharmaceutically acceptable salts thereof, selected from the group consisting of an interferon, ribavirin, a HCV protease inhibitor, a HCV polymerase inhibitor, a NS5A inhibitor, an antiviral compound, a compound of Formula (AA), a compound of Formula (BB) and a compound of Formula (CC), wherein:

Formula (AA) has the structure:



, wherein:

B^{AA1} is an optionally substituted heterocyclic base or an optionally substituted heterocyclic base with a protected amino group;

R^{AA1} is selected from O^-, OH, an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative;

R^{AA2} is absent or selected from hydrogen, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl and



, wherein R^{AA6}, R^{AA7} and R^{AA8} are independently absent or hydrogen, and n^{AA} is 0 or 1;

provided that when R^{AA1} is O^- or OH, then R^{AA2} is absent, hydrogen or



;

R^{AA3} is selected from hydrogen, halogen, $-OR^{AA9}$ and $-OC(=O)R^{AA10}$;

R^{AA4} is selected from halogen, $-OR^{AA11}$ and $-OC(=O)R^{AA12}$; or R^{AA3} and R^{AA4} are both an oxygen atom which are linked together by a carbonyl group;

R^{AA5} is selected from an optionally substituted C_{2-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{2-6} alkynyl and an optionally substituted C_{3-6} cycloalkyl; or R^{AA4} and R^{AA5} together form $-(C_{1-6}$ alkyl)-O– or –O-(C_{1-6} alkyl)–;

R^{AA9} and R^{AA11} are independently hydrogen or an optionally substituted C_{1-6} alkyl; and R^{AA10} and R^{AA12} are independently an optionally substituted C_{1-6} alkyl or an optionally substituted C_{3-6} cycloalkyl;

Formula (BB) has the structure:



, wherein:

B^{BB1} is an optionally substituted heterocyclic base or an optionally substituted heterocyclic base with a protected amino group;

X^{BB} is O (oxygen) or S (sulfur);

R^{BB1} is selected from $-Z^{BB}-R^{BB9}$, an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative;

Z^{BB} is selected from O (oxygen), S (sulfur) and $N(R^{BB10})$;

R^{BB2} and R^{BB3} are independently selected from hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{2-6} alkynyl, an optionally substituted C_{1-6} haloalkyl and an optionally substituted aryl(C_{1-6} alkyl); or R^{BB2} and R^{BB3} are taken together to form a group

selected from an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{3-6} cycloalkenyl, an optionally substituted C_{3-6} aryl and an optionally substituted C_{3-6} heteroaryl;

R^{BB4} is selected from hydrogen, halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{2-6} alkynyl and an optionally substituted allenyl;

R^{BB5} is hydrogen or an optionally substituted C_{1-6} alkyl;

R^{BB6} is selected from hydrogen, halogen, azido, amino, cyano, an optionally substituted C_{1-6} alkyl, $-OR^{BB11}$ and $-OC(=O)R^{BB12}$;

R^{BB7} is selected from hydrogen, halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, $-OR^{BB13}$ and $-OC(=O)R^{BB14}$;

R^{BB8} is selected from hydrogen, halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, $-OR^{BB15}$ and $-OC(=O)R^{BB16}$;

R^{BB9} is selected from an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted aryl(C_{1-6}alkyl), an optionally substituted heteroaryl(C_{1-6}alkyl) and an optionally substituted heterocyclyl(C_{1-6}alkyl);

R^{BB10} is selected from hydrogen, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted aryl(C_{1-6}alkyl), an optionally substituted heteroaryl(C_{1-6}alkyl) and an optionally substituted heterocyclyl(C_{1-6}alkyl);

R^{BB11}, R^{BB13} and R^{BB15} are independently hydrogen or an optionally substituted C_{1-6} alkyl; and

R^{BB12}, R^{BB14} and R^{BB16} are independently an optionally substituted C_{1-6} alkyl or an optionally substituted C_{3-6} cycloalkyl; and

Formula (CC) has the structure:



, wherein:

B^{CC1} is an optionally substituted heterocyclic base or an optionally substituted heterocyclic base with a protected amino group;

R^{CC1} is selected from O^-, OH, an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative;

R^{CC2} is selected from an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl and , wherein R^{CC19}, R^{CC20} and R^{CC21} are independently absent or hydrogen, and n^{CC} is 0 or 1; provided that when R^{CC1} is O^- or OH, then R^{CC2} is ;

R^{CC3a} and R^{CC3b} are independently selected from hydrogen, deuterium, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{2-6} alkynyl, an optionally substituted C_{1-6} haloalkyl and aryl(C_{1-6} alkyl); or R^{CC3a} and R^{CC3b} are taken together to form an optionally substituted C_{3-6} cycloalkyl;

R^{CC4} is selected from hydrogen, azido, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl and an optionally substituted C_{2-6} alkynyl;

R^{CC5} is selected from hydrogen, halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, $-OR^{CC10}$ and $-OC(=O)R^{CC11}$;

R^{CC6} is selected from hydrogen, halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, $-OR^{CC12}$ and $-OC(=O)R^{CC13}$;

R^{CC7} is selected from hydrogen, halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, $-OR^{CC14}$ and $-OC(=O)R^{CC15}$; or R^{CC6} and R^{CC7} are both oxygen atoms and linked together by a carbonyl group;

R^{CC8} is selected from hydrogen, halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, $-OR^{CC16}$ and $-OC(=O)R^{CC17}$;

R^{CC9} is selected from hydrogen, azido, cyano, an optionally substituted C_{1-6} alkyl and $-OR^{CC18}$;

R^{CC10}, R^{CC12}, R^{CC14}, R^{CC16} and R^{CC18} are independently selected from hydrogen and an optionally substituted C_{1-6} alkyl; and

R^{CC11}, R^{CC13}, R^{CC15} and R^{CC17} are independently selected from an optionally substituted C_{1-6} alkyl and an optionally substituted C_{3-6} cycloalkyl.

57. Use of a compound of any one of Claims 1-50 in the preparation of a medicament for contacting a cell infected with a hepatitis C virus, wherein the medicament is manufactured for use in combination with one or more agents, or pharmaceutically acceptable salts thereof, selected from the group consisting of an interferon, ribavirin, a HCV protease inhibitor, a HCV polymerase inhibitor, a NS5A inhibitor, an antiviral compound, a compound of Formula (AA) , a compound of Formula (BB) and a compound of Formula (CC), wherein

Formula (AA) has the structure:



, wherein:

B^{AA1} is an optionally substituted heterocyclic base or an optionally substituted heterocyclic base with a protected amino group;

R^{AA1} is selected from O^-, OH, an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative;

R^{AA2} is absent or selected from hydrogen, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl and



, wherein R^{AA6}, R^{AA7} and R^{AA8} are independently absent or hydrogen, and n^{AA} is 0 or 1;

provided that when R^{AA1} is O^- or OH, then R^{AA2} is absent, hydrogen or



;

R^{AA3} is selected from hydrogen, halogen, $-OR^{AA9}$ and $-OC(=O)R^{AA10}$;

R^{AA4} is selected from halogen, $-OR^{AA11}$ and $-OC(=O)R^{AA12}$; or R^{AA3} and R^{AA4} are both an oxygen atom which are linked together by a carbonyl group;

R^{AA5} is selected from an optionally substituted C_{2-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{2-6} alkynyl and an optionally substituted C_{3-6} cycloalkyl; or R^{AA4} and R^{AA5} together form $-(C_{1-6}$ alkyl)-O– or –O-(C_{1-6} alkyl)–;

R^{AA9} and R^{AA11} are independently hydrogen or an optionally substituted C_{1-6} alkyl; and R^{AA10} and R^{AA12} are independently an optionally substituted C_{1-6} alkyl or an optionally substituted C_{3-6} cycloalkyl;

Formula (BB) has the structure:



, wherein:

B^{BB1} is an optionally substituted heterocyclic base or an optionally substituted heterocyclic base with a protected amino group;

X^{BB} is O (oxygen) or S (sulfur);

R^{BB1} is selected from $-Z^{BB}–R^{BB9}$, an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative;

Z^{BB} is selected from O (oxygen), S (sulfur) and $N(R^{BB10})$;

R^{BB2} and R^{BB3} are independently selected from hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{2-6} alkynyl, an optionally substituted C_{1-6} haloalkyl and an optionally substituted aryl(C_{1-6} alkyl); or R^{BB2} and R^{BB3} are taken together to form a group selected from an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{3-6} cycloalkenyl, an optionally substituted C_{3-6} aryl and an optionally substituted C_{3-6} heteroaryl;

R^{BB4} is selected from hydrogen, halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{2-6} alkynyl and an optionally substituted allenyl;

R^{BB5} is hydrogen or an optionally substituted C_{1-6} alkyl;

R^{BB6} is selected from hydrogen, halogen, azido, amino, cyano, an optionally substituted C_{1-6} alkyl, $-OR^{BB11}$ and $-OC(=O)R^{BB12}$;

R^{BB7} is selected from hydrogen, halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, $-OR^{BB13}$ and $-OC(=O)R^{BB14}$;

R^{BB8} is selected from hydrogen, halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, $-OR^{BB15}$ and $-OC(=O)R^{BB16}$;

R^{BB9} is selected from an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted aryl(C_{1-6}alkyl), an optionally substituted heteroaryl(C_{1-6}alkyl) and an optionally substituted heterocyclyl(C_{1-6}alkyl);

R^{BB10} is selected from hydrogen, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted aryl(C_{1-6}alkyl), an optionally substituted heteroaryl(C_{1-6}alkyl) and an optionally substituted heterocyclyl(C_{1-6}alkyl);

R^{BB11}, R^{BB13} and R^{BB15} are independently hydrogen or an optionally substituted C_{1-6} alkyl; and

R^{BB12}, R^{BB14} and R^{BB16} are independently an optionally substituted C_{1-6} alkyl or an optionally substituted C_{3-6} cycloalkyl; and

Formula (CC) has the structure:



, wherein:

B^{CC1} is an optionally substituted heterocyclic base or an optionally substituted heterocyclic base with a protected amino group;

R^{CC1} is selected from O^-, OH, an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative;

R^{CC2} is selected from an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl and , wherein R^{CC19}, R^{CC20} and R^{CC21} are independently absent or hydrogen, and n^{CC} is 0 or 1; provided that when R^{CC1} is O^- or OH, then R^{CC2} is ;

R^{CC3a} and R^{CC3b} are independently selected from hydrogen, deuterium, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{2-6} alkynyl, an optionally substituted C_{1-6} haloalkyl and aryl(C_{1-6} alkyl); or R^{CC3a} and R^{CC3b} are taken together to form an optionally substituted C_{3-6} cycloalkyl;

R^{CC4} is selected from hydrogen, azido, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl and an optionally substituted C_{2-6} alkynyl;

R^{CC5} is selected from hydrogen, halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, $-OR^{CC10}$ and $-OC(=O)R^{CC11}$;

R^{CC6} is selected from hydrogen, halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, $-OR^{CC12}$ and $-OC(=O)R^{CC13}$;

R^{CC7} is selected from hydrogen, halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, $-OR^{CC14}$ and $-OC(=O)R^{CC15}$; or R^{CC6} and R^{CC7} are both oxygen atoms and linked together by a carbonyl group;

R^{CC8} is selected from hydrogen, halogen, azido, cyano, an optionally substituted C_{1-6} alkyl, $-OR^{CC16}$ and $-OC(=O)R^{CC17}$;

R^{CC9} is selected from hydrogen, azido, cyano, an optionally substituted C_{1-6} alkyl and $-OR^{CC18}$;

R^{CC10}, R^{CC12}, R^{CC14}, R^{CC16} and R^{CC18} are independently selected from hydrogen and an optionally substituted C_{1-6} alkyl; and

R^{CC11}, R^{CC13}, R^{CC15} and R^{CC17} are independently selected from an optionally substituted C_{1-6} alkyl and an optionally substituted C_{3-6} cycloalkyl.

58. The use of any one of Claims 56-57, wherein the one or more agents, or pharmaceutically acceptable salts thereof, are selected from the group consisting of

ABT-450, GS-9256, GS-9451, IDX-320, ACH-1625, ACH-2684, PHX1766, PSI-661, GS-6620, TMC649128, NM283, BCX5191, IDX19368, IDX19370, ABT-333, BI-207127, ABT-072, MK-3281, TMC647055, BMS-791325, PPI-383, GS9669, PPI-461, ACH-2928, GS-5885, BMS-824393, ABT 267, ACH-3102, AZD-7295, IDX719, PPI-668, MK8742, GSK805, alisporivir, MIR-122, clemizole, ITX 5061, BIT225, NIM811, SCY-635, miravirsen, GS9620,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,


,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,


















,

,

,

,

,

,

,

,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,

- 328 -


,

,

, and

.